Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GPhA And Actavis Divorcing: Biosimilars Behind The Rift

Executive Summary

Actavis, the hybridizing generics giant that once helped keep GPhA together, now appears to be splitting off in a dispute over state substitution strategy.


Related Content

For Generics Industry, Will Larger Firms Mean Weaker Lobbying?
If You Can't Beat 'Em … Hire 'Em? PhRMA Exec Is New GPhA CEO
GPhA’s Biosimilars Council Will Ratchet Up Advocacy, Seek New Partners
Biosimilar Substitution Legislation Emphasizes Electronic Health Records
FDA, WHO Biosimilar Naming Proposals Take Shape
Waiting For Biosimilars: From Manufacturing To Litigation, Stakeholders Prepare For U.S. Market
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
GPhA Enters 2011 Bigger And Stronger, But With A Broader Fight On Its Hands


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts